Maxim Group Begins Coverage on Mainz Biomed (NASDAQ:MYNZ)
Maxim Group started coverage on shares of Mainz Biomed (NASDAQ:MYNZ – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $14.00 target price on the stock. Separately, HC Wainwright downgraded shares of Mainz Biomed from a “buy” rating to a “neutral” […]
Maxim Group started coverage on shares of Mainz Biomed (NASDAQ:MYNZ – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $14.00 target price on the stock. Separately, HC Wainwright downgraded shares of Mainz Biomed from a “buy” rating to a “neutral” […]